Press Releases 2020

Biocon Biologics / News – Posts / Press Releases / Press Releases 2020

Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents

Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents

Tue, 15-Dec-2020
Posted by: Biocon Biologics

Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs

Sat, 07-Nov-2020
Posted by: Biocon Biologics

Biocon Ranked Among Top 5 Biotech Employers Globally

Fri, 30-Oct-2020
Posted by: Biocon Biologics

Biocon Q2FY21 Revenue at Rs 1,760 Cr, Up 10%; EBITDA at Rs 407 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 174 Cr; Generics Up 8% at Rs 599 Cr; Biosimilars Up 11% at Rs 676 Cr; Research Services Up 12% at Rs 520 Cr.

Fri, 23-Oct-2020
Posted by: Biocon Biologics

Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi

Thu, 08-Oct-2020
Posted by: Biocon Biologics

Biocon Biologics to Roll Out ‘Mission 10 cents’ in Philippines; Signs MoU with 2 Municipal Governments & reach52 to enable Affordable Access to Quality Insulins

Wed, 30-Sep-2020
Posted by: Biocon Biologics

Biocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes

Mon, 31-Aug-2020
Posted by: Biocon Biologics

Tata Capital Growth Fund to Invest ~USD 30 million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85% Deal Values Biocon Biologics at USD 3.5 Billion.

Fri, 31-Jul-2020
Posted by: Biocon Biologics

Biocon Q1FY21 Revenue at Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit (from continuing ops) at Rs 153 Cr Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr

Thu, 23-Jul-2020
Posted by: Biocon Biologics

Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins

Tue, 21-Jul-2020
Posted by: Biocon Biologics

1
2
3